key: cord-0960322-hw1oeucf
authors: Moreira, Thais G.; Matos, Kimble T. F.; De Paula, Giovana S.; Santana, Thais M. M.; Da Mata, Raquel G.; Pansera, Fernando C.; Cortina, Andre S.; Spinola, Marcelle G.; Baecher-Allan, Clare M.; Keppeke, Gerson D.; Jacob, Jules; Palejwala, Vaseem; Chen, Karen; Izzy, Saef; Healey, Brian C.; Rezende, Rafael M.; Dedivitis, Rogerio A.; Shailubhai, Kunwar; Weiner, Howard L.
title: Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study
date: 2022-01-12
journal: Front Immunol
DOI: 10.3389/fimmu.2021.815812
sha: ab60a29e84530df021509720ac316dbd4720ed7f
doc_id: 960322
cord_uid: hw1oeucf

[This corrects the article DOI: 10.3389/fimmu.2021.709861.].

"TM designed the study, led and monitored this clinical study, and wrote the manuscript. KM designed the study, clinically monitored the study, and performed Lung CT analysis. GD and TS recruited patients, performed clinical exams, registered drug intake and medical past history. RGD, monitored the study and helped collect BMI data. FP and AC supported patient recruitment. MS performed biomarkers assays. CMB-A participated in drug development. GK performed serum and plasma collection. JJ and VP performed drug stability assays. SI and KC performed Lung CT scan analysis. BH performed statistical analysis. RR designed the study and reviewed manuscript. RAD helped supervise the study at Santa Casa de Santos Hospital. KS helped design the study and reviewed the manuscript. HW designed the study and helped write the manuscript.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited

All authors contributed to the article and approved the submitted version."